期刊文献+

利伐沙班对预防下肢深静脉血栓形成的进展 被引量:2

Evolution of the Rivaroxaban to Take Precautions Against Formation of the Phlebothrombosis
下载PDF
导出
摘要 目的:探讨利伐沙班对预防下肢骨折术后深静脉血栓形成的效果。方法:对58例患者骨折内固定术、人工髋关节置换术后下肢深静脉血栓形成的预防。结果:57例无静脉血栓形成,仅1例患者深静脉血栓形成,通过治疗后痊愈,有效率98.27%。结论:利伐沙班对预防下肢深静脉血栓形成可获得良好的效果。 Objective: this paper focuses on the study the effection of the Rivaroxaban to take precautions against formation of the Phlebothrombosis after the fracture operation; Methords: precautions against formation of the Phlebothrombosis after the fracture pexis, artificial hip to 58 patients; Results :no Phlebothrombosis for 57 patients, except for 1 patient, and the efficiency is up to as high as 98.27%; Conclusion.. there is a good effect of the Rivaroxaban to take precautions against formation of the Phlebothrombosis.
作者 练琼芳
出处 《心血管病防治知识(学术版)》 2011年第3期1-2,共2页 Prevention and Treatment of Cardiovascular Disease
关键词 利伐沙班 预防 深静脉血栓 Rivaroxaban precautions Phlebothrombosis
  • 相关文献

参考文献8

二级参考文献68

共引文献135

同被引文献36

  • 1张治云,凌沛学,王凤山,张天民.低分子肝素药理作用研究进展[J].食品与药品,2006,8(01A):7-9. 被引量:24
  • 2国家"十五"攻关"肺栓塞规范化诊治方法的研究"课题组,杨媛华,翟振国,武燕兵,王辰.急性肺血栓栓塞症患者516例临床表现分析[J].中华医学杂志,2006,86(31):2161-2165. 被引量:79
  • 3Hauel N H,Nar H,Priepke H. Structure-based design of novel potent nonpeptide thrombin inhibi-tors[J].Journal of Medicinal Chemistry,2002,(09):1757-1766.doi:10.1021/jm0109513.
  • 4Zerban G,Hausherr A,Schlarb K. Method forproducing 4-(benzimidazolylmethylamino)-benza midines[P].WO,2006/000353,2006.
  • 5Connolly S J,Ezekowitz M D,Yusuf S. Dabig-arran versus Warfarin in patients with atrial fibril-lation[J].New England Journal of Medicine,2009,(02):1139-1151.
  • 6Bogatkevich G S,Ludwicka B A,Nietert P J. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease[J].Arthri-tis and Rheumatism,2011,(05):1416-1425.
  • 7Huo M H,Kurth A A,Dahl 0 E. Oral Dabigat- ran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip or knee arthroplasty.-A pooled analysis of four randomized trials[J].Blood,2011,(21):1002.
  • 8Gage B F. Can we rely on RE-LY[J].New England Journal of Medicine,2009,(12):1200-1212.
  • 9Straub A,Lampe T,Pohlmann J. Substituted oxazolidinones and their use in the field of blood coagulation[P].WO,2001047919,2001.
  • 10Christian R Thomas. Method for producing 5-chloro-N-({ 5s-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl }-methyl)-2-thiophenecar-boxamide[P].US,20070149522AlePh,2007.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部